Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 20, 2025Open Access

Targeting NRF2 and FSP1 to Overcome Ferroptosis Resistance in TSC2-Deficient and Cancer Cells

View Full Paper
Ask AI
Bookmark
Share

Authors

TTTasmia TahsinBetsi Cadwaladr University Health BoardDMDarius K. McPhailSwansea UniversityJCJesse D. ChampionCardiff University

Discussion

Loading...

Member takes

Implication

Observational analysis finds that dual targeting of NRF2 and FSP1 increases ferroptosis sensitivity in cancer, suggesting new treatment strategies.

Key Points

  • TSC2-deficient cells resist ferroptosis due to antioxidant responses, highlighting significant resistance mechanisms.
  • Targeting NRF2 re-sensitized TSC2-deficient cells to ferroptosis, while FSP1 inhibition enhanced sensitivity in cancer cells.
  • Assessment using inhibitors of NRF2 and FSP1 demonstrated varied responses across cell lines, indicating differential efficacy.
  • These findings may direct therapeutic strategies, emphasizing the importance of patient-specific treatment approaches in cancer.

Cite This Study

Tahsin et al. (2025) studied this question.

synapsesocial.com/papers/68af6d847567bf4f94fea7d7https://doi.org/10.20944/preprints202504.0343.v2
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Targeting NRF2 and FSP1 to Overcome Ferroptosis Resistance in TSC2-Deficient and Cancer Cells2025 · 8 citations
  2. 2Targeting FSP1 triggers ferroptosis in lung cancer2025 · 3 citations
  3. 3Roles and Prospective Applications of Ferroptosis Suppressor Protein 1 (FSP1) in Malignant Tumor Treatment2025 · 9 citations
  4. 4Ferroptosis and Nrf2 Signaling in Head and Neck Cancer: Resistance Mechanisms and Therapeutic Prospects2025 · 16 citations
  5. 5Ferroptosis as a Therapeutic Avenue in Triple-Negative Breast Cancer: Mechanistic Insights and Prognostic Potential2025 · 5 citations